English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background Extended spectrum beta-lactamase (ESBL) pathogens are associated with morbidity and mortality. There is a paucity of data describing the treatments and outcomes of ESBL infections in Malaysia. This study evaluated the treatments, mortality and associated factors among patients hospitalized with infections due to ESBL positive  enterobacteriaceae . This is a retrospective study conducted in a tertiary hospital from January 2018 to June 2020. Hospitalized patients with ESBL-positive  enterobacteriaceae  infections were included. A clinical pharmacist collected data by reviewing the patients’ electronic medical records. The data were analysed using both descriptive and inferential analyses. Results This analysis included 110 patients with a mean age of 62.1 ± 14.4 years.  Klebsiella pneumoniae  (53.6%) and  Escherichia coli  (40.9%) were the most prevalent pathogens among the 110 infections. Bacteremia (42.7%) was the most frequent diagnosis. The isolates were resistant to majority of penicillins and cephalosporins. However, over a third (39.3%) were susceptible to piperacillin–tazobactam, while carbapenem susceptibility was extremely high (≥ 99%). The most frequently used empiric and definitive antibiotics was piperacillin–tazobactam and meropenem, respectively. Less than a third (28.2%) of patients received active empiric antibiotics, and the mean duration before active antibiotics was 3.9 ± 2.7. Overall, hospital mortality rate was 13.6%, and mortality was significantly associated with ICU admission (AOR 8.75; 95% CI 1.05–72.75;  P  = 0.045) and diabetes mellitus (AOR 9.85; 95% CI 1.04–93.09;  P  = 0.046). Conclusions Carbapenems are the major antibiotics used to treat ESBL-positive  enterobacteriaceae  infections. Hospital mortality rate is relatively high and is significantly associated with  in patients admitted to ICU and those with diabetes mellitus. Antibiotic stewardship interventions are necessary to promote early administration of active antibiotics and to reduce overuse of carbapenem antibiotics.

future journal of pharmaceutical sciences

Mortality and its predictors among hospitalized patients with infections due to extended spectrum beta-lactamase (ESBL) Enterobacteriaceae in Malaysia: a retrospective observational study